Oncology and Hematology - MedEd On The Go

Episodes 17-32 of 57

Biologic Rationale for Targeting HER3 and Role in EGFR Resistance
Biologic Rationale for Targeting HER3 and Role in EGFR Resistance
MinuteCE®
Biologic Rationale for Targeting HER3 and Role in EGFR Resistance
0.75 program credits
- Pasi Antero Jänne, MD, PhD
0.75 program credits
Expert Peer Discussion: Integrating Novel HER3-Directed ADCs Upon Disease Progression Following EGFR TKI and Platinum Chemotherapy
Expert Peer Discussion: Integrating Novel HER3-Directed ADCs Upon Disease Progression Following EGFR TKI and Platinum Chemotherapy
MinuteCE®
Expert Peer Discussion: Integrating Novel HER3-Directed ADCs Upon Disease Progression Following EGFR TKI and Platinum Chemotherapy
0.75 program credits
- Pasi Antero Jänne, MD, PhD
- Helena Yu, MD
0.75 program credits
MinuteCE®
HER3-Directed ADCs in the Treatment of EGFR-Mutated Advanced or Metastatic NSCLC Progressing on TKI and Platinum-Based Chemotherapy
0.75 credits 6 episodes
- Pasi Antero Jänne, MD, PhD
- Helena Yu, MD
0.75 credits 6 episodes
Interprofessional Monitoring and Management of AEs With HER3-Directed ADCs
Interprofessional Monitoring and Management of AEs With HER3-Directed ADCs
MinuteCE®
Interprofessional Monitoring and Management of AEs With HER3-Directed ADCs
0.75 program credits
- Helena Yu, MD
- Pasi Antero Jänne, MD, PhD
0.75 program credits
Overcoming EGFR Resistance With HER3-Directed ADCs
Overcoming EGFR Resistance With HER3-Directed ADCs
MinuteCE®
Overcoming EGFR Resistance With HER3-Directed ADCs
0.75 program credits
- Helena Yu, MD
0.75 program credits
Case Application: Adverse Event Management of Patients With EGFRm Resistance Treated With Novel HER3-Directed ADCs
Case Application: Adverse Event Management of Patients With EGFRm Resistance Treated With Novel HER3-Directed ADCs
MinuteCE®
Case Application: Adverse Event Management of Patients With EGFRm Resistance Treated With Novel HER3-Directed ADCs
0.75 program credits
- Helena Yu, MD
- Pasi Antero Jänne, MD, PhD
0.75 program credits
The Weight of Recurrence: Navigating Multidisciplinary Care Planning in Recurring/Metastatic Cervical Cancer
The Weight of Recurrence: Navigating Multidisciplinary Care Planning in Recurring/Metastatic Cervical Cancer
CME/CE
The Weight of Recurrence: Navigating Multidisciplinary Care Planning in Recurring/Metastatic Cervical Cancer
0.25 credits
- Brian Slomovitz, MD
- Robert L. Coleman, MD, FACOG, FACS
0.25 credits
Differentiating Biomarker-Driven First-Line Treatment Strategies in Metastatic Gastric/GEJ Cancers
Differentiating Biomarker-Driven First-Line Treatment Strategies in Metastatic Gastric/GEJ Cancers
CME/CE Broadcast Replay
Differentiating Biomarker-Driven First-Line Treatment Strategies in Metastatic Gastric/GEJ Cancers
0.75 credits
- Nataliya Uboha, MD, PhD
0.75 credits
Bringing Treatment Into Focus: Biomarker-Driven First-Line Therapy for Metastatic Gastric/GEJ Cancers
Bringing Treatment Into Focus: Biomarker-Driven First-Line Therapy for Metastatic Gastric/GEJ Cancers
CME/CE
Bringing Treatment Into Focus: Biomarker-Driven First-Line Therapy for Metastatic Gastric/GEJ Cancers
1.00 credit
- David H. Ilson, MD, PhD
- Sunnie Kim, MD
1.00 credit
Patient Case: How Do HER2-Directed Therapies Fit Into the Biliary Tract Cancer Treatment Landscape?
Patient Case: How Do HER2-Directed Therapies Fit Into the Biliary Tract Cancer Treatment Landscape?
MinuteCE®
Patient Case: How Do HER2-Directed Therapies Fit Into the Biliary Tract Cancer Treatment Landscape?
0.75 program credits
- Ritu Salani, MD, MBA
0.75 program credits
Diversity in HER2 Expression Among Gynecologic Cancers
Diversity in HER2 Expression Among Gynecologic Cancers
MinuteCE®
Diversity in HER2 Expression Among Gynecologic Cancers
0.75 program credits
- Ritu Salani, MD, MBA
0.75 program credits
Emerging Data Evaluating HER2-Directed Therapies in Gynecologic Cancers
Emerging Data Evaluating HER2-Directed Therapies in Gynecologic Cancers
MinuteCE®
Emerging Data Evaluating HER2-Directed Therapies in Gynecologic Cancers
0.75 program credits
- Ritu Salani, MD, MBA
0.75 program credits
Pivotal Data on Targeting HER2 in HER2-Expressing Solid Tumors
Pivotal Data on Targeting HER2 in HER2-Expressing Solid Tumors
MinuteCE®
Pivotal Data on Targeting HER2 in HER2-Expressing Solid Tumors
0.75 program credits
- Shubham Pant, MD, MBBS
0.75 program credits
Significance of HER2 Expression in Solid Tumors
Significance of HER2 Expression in Solid Tumors
MinuteCE®
Significance of HER2 Expression in Solid Tumors
0.75 program credits
- Shubham Pant, MD, MBBS
- Ritu Salani, MD, MBA
0.75 program credits
HER2 Testing Strategies Across Tumor Types Amidst Guidelines Gaps
HER2 Testing Strategies Across Tumor Types Amidst Guidelines Gaps
MinuteCE®
HER2 Testing Strategies Across Tumor Types Amidst Guidelines Gaps
0.75 program credits
- Shubham Pant, MD, MBBS
0.75 program credits
Patient Case: How Do HER2-Directed Therapies Fit Into the Ovarian Cancer Treatment Landscape?
Patient Case: How Do HER2-Directed Therapies Fit Into the Ovarian Cancer Treatment Landscape?
MinuteCE®
Patient Case: How Do HER2-Directed Therapies Fit Into the Ovarian Cancer Treatment Landscape?
0.75 program credits
- Ritu Salani, MD, MBA
0.75 program credits

2/4